520 related articles for article (PubMed ID: 30612559)
21. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
Kyriazopoulou E; Sinapidis D; Halvatzis S; Velissaris D; Alexiou N; Kosmas V; Adami ME; Kyprianou M; Kyprianou A; Stefos A; Lada M; Koutoukas P; Pavlaki M; Kyriakoudi A; Makina A; Gogos C; Niederman MS; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2020 Jan; 55(1):105836. PubMed ID: 31704213
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
[TBL] [Abstract][Full Text] [Related]
23. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
[TBL] [Abstract][Full Text] [Related]
24. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
van Werkhoven CH; Postma DF; Oosterheert JJ; Bonten MJ
Neth J Med; 2014 Apr; 72(3):170-8. PubMed ID: 24846935
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
26. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.
Vardakas KZ; Siempos II; Grammatikos A; Athanassa Z; Korbila IP; Falagas ME
CMAJ; 2008 Dec; 179(12):1269-77. PubMed ID: 19047608
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
Kılıç Soylar Ö; Kılınç O; Ellidokuz H
Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
[TBL] [Abstract][Full Text] [Related]
28. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
[TBL] [Abstract][Full Text] [Related]
29. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
30. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
[TBL] [Abstract][Full Text] [Related]
31. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
[TBL] [Abstract][Full Text] [Related]
32. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
33. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
[TBL] [Abstract][Full Text] [Related]
34. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
[TBL] [Abstract][Full Text] [Related]
35. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.
Wilson BZ; Anzueto A; Restrepo MI; Pugh MJ; Mortensen EM
Crit Care Med; 2012 Aug; 40(8):2310-4. PubMed ID: 22622401
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
[TBL] [Abstract][Full Text] [Related]
37. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
Mortensen EM; Restrepo MI; Anzueto A; Pugh J
Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
[TBL] [Abstract][Full Text] [Related]
38. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H
J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381
[TBL] [Abstract][Full Text] [Related]
39. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
40. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
